Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 1:31 AM ET


Company Overview of Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Company Overview

Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, distribution, and sale of biological products and chemical drugs in China. The company primarily provides tablets, powders, capsules, injections, and others. Its products include Su peptide Health, an injection for the treatment of optic nerve damage; Shu Taiqing, a polyethylene glycol electrolyte powder, which is applied in the bowel cleansing and used for the treatment of constipation; Gliclazide tablets for type 2 diabetes; and Aspirin, a non-steroidal anti-inflammatory drug. The company also offers Nabumetone capsules for the treatment of acute and chronic inflammatory arthritis, soft tissu...

Beijing Economic and Technological Development Zone

No. 36 Sea Road

Beijing,  100176


Founded in 2002


86 10 6751 9888


86 10 6751 9794

Key Executives for Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Staidson (Beijing) Biopharmaceuticals Co., Ltd. does not have any Key Executives recorded.

Staidson (Beijing) Biopharmaceuticals Co., Ltd. Key Developments

Staidson (Beijing) Biopharmaceuticals Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 14, 2015

Staidson (Beijing) Biopharmaceuticals Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 14, 2015., at 09:00 China Standard Time. Agenda: To consider re-election of Zhou Zhiwen, Jiang Lixin, Zhou Yi, Gu Zhenqi, Chen Hao and Duan Jidong as non-independent directors; to consider election of Zhao Jialiang, Wu Songsheng and Gong Zhaolong as independent directors; to consider re-election of Zhang Hongshan and Ye Qing as supervisors; to consider restricted stock incentive plan (draft) and its summary; to consider the stock appreciation right incentive plan(draft) and its summary; to consider implementation and appraisal management measures for the stock incentive plan; to consider authorization to the board to handle matters in relation to the company's stock incentive plan; and to consider adjustment to the allowance for independent directors.

Staidson (Beijing) Biopharmaceuticals Co., Ltd. to Report First Half, 2015 Results on Aug 25, 2015

Staidson (Beijing) Biopharmaceuticals Co., Ltd. announced that they will report first half, 2015 results on Aug 25, 2015

Staidson (Beijing) Biopharmaceuticals Co., Ltd. to Report Q1, 2015 Results on Apr 24, 2015

Staidson (Beijing) Biopharmaceuticals Co., Ltd. announced that they will report Q1, 2015 results on Apr 24, 2015

Recent Private Companies Transactions

Private Placement
August 23, 2015
Beijing Defengrui Biotechnology Co., Ltd.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Staidson (Beijing) Biopharmaceuticals Co., Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at